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Abstract
Background: Fragile X syndrome (FXS) is a neurodevelopmental disorder whose biochemical manifestations
involve dysregulation of mGluR5-dependent pathways, which are widely modeled using cultured neurons. In
vitro phenotypes in cultured neurons using standard morphological, functional, and chemical approaches have
demonstrated considerable variability. Here, we study transcriptomes obtained in situ in the intact brain tissues of
a murine model of FXS to see how they reflect the in vitro state.
Methods: We used genome-wide mRNA expression profiling as a robust characterization tool for studying
differentially expressed pathways in fragile X mental retardation 1 (Fmr1) knockout (KO) and wild-type (WT) murine
primary neuronal cultures and in embryonic hippocampal and cortical murine tissue. To study the developmental
trajectory and to relate mouse model data to human data, we used an expression map of human development to
plot murine differentially expressed genes in KO/WT cultures and brain.
Results: We found that transcriptomes from cell cultures showed a stronger signature of Fmr1KO than whole tissue
transcriptomes. We observed an over-representation of immunological signaling pathways in embryonic Fmr1KO
cortical and hippocampal tissues and over-represented mGluR5-downstream signaling pathways in Fmr1KO cortical
and hippocampal primary cultures. Genes whose expression was up-regulated in Fmr1KO murine cultures tended to
peak early in human development, whereas differentially expressed genes in embryonic cortical and hippocampal
tissues clustered with genes expressed later in human development.
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Conclusions: The transcriptional profile in brain tissues primarily centered on immunological mechanisms, whereas
the profiles from cell cultures showed defects in neuronal activity. We speculate that the isolation and culturing
of neurons caused a shift in neurological transcriptome towards a “juvenile” or “de-differentiated” state. Moreover,
cultured neurons lack the close coupling with glia that might be responsible for the immunological phenotype in
the intact brain. Our results suggest that cultured cells may recapitulate an early phase of the disease, which is also
less obscured with a consequent “immunological” phenotype and in vivo compensatory mechanisms observed in
the embryonic brain. Together, these results suggest that the transcriptome of cultured primary neuronal cells, in
comparison to whole brain tissue, more robustly demonstrated the difference between Fmr1KO and WT mice
and might reveal a molecular phenotype, which is typically hidden by compensatory mechanisms present in vivo.
Moreover, cultures might be useful for investigating the perturbed pathways in early human brain development
and genes previously implicated in autism.
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Background
Fragile X syndrome (FXS) is the most common inherited
form of mental retardation and the most common genetic
cause of autism. It is caused by loss-of-function mutations
in the gene fragile X mental retardation 1 (Fmr1) and a
consequent loss of its product, fragile X mental retard-
ation protein (FMRP) [1–3]. The pathophysiology of FXS
involves dysregulation of numerous pathways. Recent
studies have begun to provide insights into the biology of
FMRP, and the results converged on metabotropic glu-
tamate receptor (mGluR) signaling theory [1, 2]. Huber
et al. discovered that a form of synaptic plasticity, mGluR-
dependent long-term synaptic depression (mGluR-LTD)
was exaggerated in Fmr1 knockout mice (Fmr1KO) [4].
This discovery led to the mGluR theory of FXS [1], which
suggests that many of its clinical features are due to exag-
gerated responses to activation of mGluR5. This theory
was validated when multiple FXS phenotypes were res-
cued in Fmr1KO mice by reducing the production of
mGluR5 protein [5–7].
Neurons from Fmr1KO mice and from patients with FXS
consistently have increased spine densities, as well as longer
spines, reminiscent of immature filopodia [5, 8–11]. Add-
itional synaptic phenotypes, including hyper-connectivity
and exaggerated responses to mGluR5 activation, are also
found in Fmr1KO mice [4, 5]. These phenotypes can be
recapitulated in cultured neurons [12, 13]. They can be
corrected by treatment with mGluR5 antagonists in both
cultured neurons and mice [5, 13]. Thus, in vitro models
derived from Fmr1KO mice are reasonable platforms for
modeling synaptic alterations occurring in FXS. Whether
these in vitro models also mirror in vivo whole-brain tran-
scriptional regulation has been less studied.
Animal models may be useful for studying the mech-
anism of disease in FXS, but current methods for char-
acterizing neuronal phenotypes in these models may not
be sufficiently robust for high-throughput pre-clinical
screening of potential drugs. Furthermore, the molecular
phenotypes are themselves heterogeneous. Therefore, iden-
tifying stable molecular phenotypes and finding a suitably
robust characterization assay is a high priority.
Recent work has shown that RNA expression signatures
can identify shared subsets of pathogenic pathways and
produce short lists of affected marker genes in a variety of
diseased tissues [14, 15]. Done correctly, this process can
define a transcriptomic landscape of diseases and tissues
and provide directionality with which to measure pertur-
bations “to” and “from” the diseased status. Shared or
partially overlapping mechanisms underlie complex phe-
notypes and may constitute a smaller set of pathways than
the number of genetic variants or the genes that contain
them. We hypothesized that genome-wide transcriptomic
arrays would provide more accurate phenotypic readouts
across various tissues and that subsequent comprehensive
pathway-level analysis could pinpoint mechanisms rele-
vant to a disease, whereas other morphological methods
provide limited phenotypic information.
Our original motivation was to determine how well cell-
culture transcriptomes recapitulate differences found in
situ in the intact brain tissues of a murine model of FXS.
Here, we studied in vitro cultured hippocampal and
cortical neurons from Fmr1KO and wild-type (WT) mice
and compared them to primary brain tissue. We also
compared the location of each of these transcriptomes in
the human transcriptomic developmental trajectories to
determine how the Fmr1KO state affected the transcrip-
tomic “age” [16, 17] in situ and in culture. We found that
this examination of transcriptional changes is able to pro-
vide greater resolution on the differences between disease
and wild-type conditions.
Methods
Ethics statement
All animal experiments were conducted in accordance
with the rules and regulations of the Institutional Animal
Care and Use Committee at the Massachusetts Institute of
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Technology (MIT). Fmr1KO mice were originally ob-
tained from The Jackson Laboratory (Bar Harbor, ME).
The strain was maintained on a C57BL/6 background for
at least six generations at MIT. All experiments were per-
formed blind to genotype and were carried out on ex vivo
brain tissue following euthanasia. Euthanasia methods are
compatible with the recommendations of the Panel on
Euthanasia of the American Veterinary Association.
Neuronal culture, tissue isolations, and RNA extraction
Hippocampal and cortical neuron cultures were prepared
from C57BL/6 congenic WT and Fmr1KO embryos at 17–
18 days post-conception (E17–E18) in parallel and allowed
to mature for 14 days in vitro (DIV) as previously described
[18]. Five pairs of biological replicates for WTand Fmr1KO
were processed on the same day. Cells were seeded at a
concentration of 150,000/mL and maintained in Neuroba-
sal media supplemented with B27, penicillin/streptomycin,
and glutamax (Invitrogen) according to the manufacturer’s
instructions. Cells were harvested on day 14 in PBS and
snap frozen using dry ice. The estimated percentage of glial
cells at 14 DIV is ~30 %. In parallel to the establishment of
primary cultures, ~10 % of hippocampal and cortical tis-
sues were dedicated to tissue analyses and stored in RNA-
later for stabilization until further processing.
Four separate sample types were used per genotype
(WT or KO): primary cortex (n = 5), primary hippo-
campus (n = 6), cortical culture (n = 5), and hippocampal
culture (n = 5). Use of duplicates resulted in 42 samples.
RNA was extracted using the miRNeasy Mini Kit (Qiagen).
Eluted RNA was analyzed on a NanoDrop ND-1000
Spectrophotometer and an Agilent 2100 Bioanalyzer
(OD260/280 ratio: 1.8–2.2; RNA Integrity Number >8).
Transcriptome profiling using microarrays
A total of 100 ng of RNA was processed using Affyme-
trix (Affymetrix Inc, Santa Clara, CA) protocols and kits,
which were used to generate biotinylated amplified RNA
(aRNA) and for hybridization, staining, and scanning of
arrays (GeneChip 3’IVT Express Kit and GeneChip
Expression Wash, Stain and Scan protocol). Total RNA
was reverse-transcribed to synthesize double-stranded
cDNA using T7 oligo(dT) primers and then transcribed
in vitro into biotin-modified aRNA with IVT Labeling
Master Mix. The aRNA was purified, quantified, and
fragmented. Fragmented aRNA was hybridized onto Affy-
metrix Mouse Genome 430 2.0 arrays and scanned on an
Affymetrix GeneChip scanner 3000 at 2.5 μm resolution.
Microarray data are deposited at the Gene Expression
Omnibus database (GSE71034).
Microarray analysis and pathway-level analysis
Expression values were extracted and normalized from
.CEL files using the Affy package and the robust multi-
array average (RMA) method in R/BioConductor (http://
www.bioconductor.org), returning the measured gene
expression signal of each microarray gene probe in a loga-
rithmic base 2 scale. Differential gene expression analysis
was performed using a linear regression model (lmFit) as
implemented in the limma package in R/BioConductor,
and significant differentially expressed probes (p < 0.05)
were extracted. We used the Database for Annotation,
Visualization and Integrated Discovery (DAVID, http://
david.abcc.ncifcrf.gov) to identify enriched pathways in
differentially expressed genes at a Fisher exact p value
threshold (EASE score) less than 0.1, which were anno-
tated with Entrez IDs. We annotated 45,101 probes with
21,141 unique Entrez Gene IDs by selecting the smallest
Entrez Gene ID for any probe originally assigned to >1 ID.
For pathway-level analysis, we focused on the Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathways.
Additionally, we performed pathway-level analysis using
MetaCore software (Gene Go Inc., St. Joseph, MI). En-
richment analysis consisted of mapping Entrez Gene
IDs of differentially expressed genes in culture and in
brain onto IDs in entities of built-in functional ontol-
ogies represented in MetaCore by process networks
and diseases to identify biological processes that were
over-represented.
Principal component analysis (PCA) was used to
characterize the directions of maximal transcriptomic
variance in the whole dataset [19–21]. PCA was per-
formed on an RMA-normalized, ranked, and standardized
matrix (mean zero and variance one) of 42 samples
(45,101 probes represented on the array). The per-
centage variance captured by each of the first two
principal components (PCs) were 61.3 % by PC1 and
11 % by PC2.
We examined the over-representation of differentially
expressed genes in Fmr1KO hippocampal and cortical
culture and embryonic brain tissues and three lists of
genes associated with defects in cognitive development
(Additional file 1: Table S1):
(1)MGI genes associated with the behavioral/
neurological phenotype in mice [22]
A search for the term “MP:0005386” in
the JAX lab mouse database (http://
www.informatics.jax.org/marker/) returned
3005 unique gene symbols, which are 2622
unique genes mapped to Entrez Gene IDs,
out of which 2462 were measured on the
Affymetrix Mouse Genome 430 2.0 microarray.
(2)Human genes from SFARI [23]: 705 genes, out of
which 645 were mapped to mouse genes
(3)FMRP binding targets as identified by Ascano et al.
[24]: 939 genes, out of which 898 were mapped to
mouse genes
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Human brain transcriptome data processing and
integration with mouse data
A spatio-temporal transcriptome of the developing hu-
man brain (human brain transcriptome (HBT)) has been
described previously [25], and these data are publicly
available in NIH’s Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo) as GSE25219. These samples
were profiled on Affymetrix Human Exon 1.0 ST Array,
and we used the transcript (gene)-to-sample series matrix
for the further analysis. In order to integrate mouse and
human gene expression data, we converted 45,101 probes
from the Mouse Affymetrix 430 Plus 2.0 array to 21,141
unique Entrez Gene IDs by selecting the smallest Entrez
Gene ID for any probe originally assigned to >1 ID. For
each differential comparison in mouse data, probe-to-
gene unique-ing was done by picking the probe with
smallest p value to represent the gene. After down-
loading human brain transcriptome data from GEO,
we converted 17,565 probes to 16,492 unique min hu-
man Entrez Gene IDs, 14,653 unique corresponding
min homologous mouse Entrez Gene IDs, and 13,830
unique mouse Entrez Gene IDs in common with the
Affymetrix Mouse Genome 430 2.0 microarray. We re-
stricted analysis of human data to hippocampus (HIP) and
neocortex (NCX) at 15 developmental stages. NCX data
included 11 areas collectively referred as the NCX region.
In the NCX data for each probe, we computed the sum of
coefficients of variance (coefvar) in stages 2–15. For each
gene, we selected the probe with the minimal sum of
coefvar for probe-to-gene unique-ing. We used the same
probes for HIP probe-to-gene unique-ing. In all analyses
comparing the two datasets above, we restricted data to
13,830 mouse genes in common between the datasets.
PCA of genes in the sample space was performed on
936 human NCX samples and 82 human HIP samples
separately, and k-means clustering (k = 3) was used to
generate temporal clusters. Before the PCA of human
data, each individual sample, a vector of 13,830 genes, was
first normalized to mean zero and variance one. Principal
components were invariant under affine transformations.
Results
Gene expression profiles in embryonic brain tissue
capture fewer genotype-based differences than primary
neuronal cultures
In order to find gene expression differences between the
FXS and healthy states, we extracted embryonic hippo-
campal and cortical tissues from Fmr1KO and WT mice
at the age of 17–18 days post-conception (E17–E18). One
portion of the tissue was used to create primary neuronal
cultures, and the other was used directly in the study of
brain tissue.
Total RNA (100 ng) from each sample was extracted,
amplified, labeled, and hybridized on Mouse Genome
430 2.0 Arrays (Affymetrix, Santa Clara, CA). Principal
component analysis (PCA) was used to characterize the
directions of maximal transcriptomic variance in the
whole dataset (Fig. 1, each dot signifies a sample). The
PCA captured 72.4 % of total variation in the data with
the first two principal components (PCs) – 61.3 % cap-
tured by PC1 and 11.1 % by PC2. This analysis indicated
that the greatest difference was observed between cultured
cells and whole tissue, representing the effects of prepar-
ation, growth, and differentiation. The second greatest
difference was between hippocampal and cortical tissue,
representing different brain regions. In addition, Fig. 1
shows that transcriptomic scale differences between two
genotypes Fmr1KO and WT are greater in the cultured
neurons versus whole embryonic cortical and hippocam-
pal tissue. Additional file 2: Table S2 shows the metrics
used to represent the difference between Fmr1KO and
WT mice. The PC1-axis centroid distance between KO
and WT clusters in both cultures was at least three times
greater than the distance between KO and WT in primary
brain. In addition, the number of significant differentially
expressed genes at an unadjusted p value of 0.05 was
almost four times greater in vitro than in whole tissues.
Our analysis identified differentially expressed genes
(p value <0.05) in Fmr1KO versus WT as follows: 2648
in hippocampal culture, 3372 in cortical culture, 726 in
primary hippocampus, and 866 in primary cortex (Add-
itional file 3: Table S3). Fmr1 was the most significantly
down-regulated gene in all systems studied (~twofold
down-regulation with p value <3.75E−15).
Enriched biological pathways converge on mGluR5-
downstream signaling pathways in cultured neurons,
while the pathways in embryonic brain tissues center on
genes associated with immunological signaling
Differential gene expression analysis was performed using
a linear regression model as implemented in the limma
library package in R/BioConductor, and significant differ-
entially expressed probes (p < 0.05) were extracted. We
used unadjusted p value < 0.05 for significance threshold.
Next, Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway-enrichment analysis of differentially expressed
genes between KO and WT was performed using the
Database for Annotation, Visualization and Integrated
Discovery (DAVID; Table 1 and Additional file 4:
Table S4).
The KEGG pathways that were most significantly
enriched with the differentially expressed genes in Fmr1KO
cultured cells and isolated embryonic hippocampal and
cortical tissues were related to synaptic signaling, immuno-
logical response, and cell-cell interactions. Sixteen path-
ways were significantly enriched in Fmr1KO hippocampal
culture compared to WT equivalent cultures (Table 1).
Six have been extensively implicated in synaptic signaling.
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They include “insulin signaling pathway” (p value = 0.001),
“long-term potentiation (LTP)” (p value = 0.003), “axon
guidance” (p value = 0.009), “gap junction” (p value =
0.017), “neurotrophin signaling pathway” (p value = 0.017)
and “mTOR signaling pathway” (p value = 0.08). Eight path-
ways were significantly enriched in Fmr1KO cortical cul-
tures (Table 1), including “neurotrophin signaling pathway”
(p value = 0.006), “MAPK signaling pathway” (p value =
0.016), and “long-term potentiation” (p value = 0.052). Five
pathways were significantly enriched in Fmr1KO in
situ hippocampus studies relating to immunological re-
sponse (such as “cytokine-cytokine receptor interaction”
(p value = 0.013)) and cell adhesion (“cell adhesion mole-
cules” (p value = 0.017)). Two pathways were significantly
enriched in Fmr1KO primary cortex. One of them was
“arachidonic acid metabolism” (p value = 0.016), which
has a role in inflammation and formation of an im-
portant group of inflammatory mediators. Several syn-
aptic mGluR5-coupled signaling pathways perturbed in
KO versus WT in cortical and hippocampal neuronal
cultures include genes that may have roles in FMRP-
regulated mRNA translation at the synapse (Additional
file 5: Table S5). Importantly, the signature in embryonic
brain tissue was primarily immunological, compared to a
primarily synaptic signature in the cultured samples.
To validate and reproduce our findings, we also per-
formed pathway-enrichment analysis on differentially
expressed genes in culture and in brain using a separate
tool, MetaCore, with similar outcomes. Networks associ-
ated with neuronal processes were over-represented in
cultures (Development_Neurogenesis_Axonal Guidance,
Additional file 6: Figure S1A). In contrast, networks
associated with immune disorders were over-represented
in brain samples (Autoimmune Diseases, Additional file
6: Figure S1B).
In addition to analyzing each system separately, we
also examined the overlap of pathways and commonal-
ities between embryonic brain and cultures and between
two different brain regions (cortex and hippocampus;
Additional file 7: Table S7). The commonalities between
cortical and hippocampal cultures converged on path-
ways such as “ribosome,” “neurotrophin signaling pathway,”
“long-term potentiation,” “endocytosis,” and “spliceosome,”
which mostly relate to synaptic signaling. In brain, we
observed convergence on the “cell adhesion molecules”
pathway between hippocampus and cortex.
We examined the over-representation of differentially
expressed genes in Fmr1KO cultures and brain tissues
for three gene sets associated with cognitive develop-
ment defects: (1) Mouse Gene Informatics (MGI) genes
associated with behavioral/neurological phenotypes [22];
(2) human autism candidate genes from Simons Founda-
tion Autism Research Initiative (SFARI) [23]; and (3)
FMRP binding targets [24] (Additional file 8: Table S8).
Primary tissueCulture
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Fig. 1 Principal component analysis (PCA) of global transcriptional profiles in murine Fmr1KO/WT culture and brain tissues. PCA captures the
differences between primary tissue or culture type and region of the brain as identified by expression levels of 45,101 probes in 42 samples.
The scatter indicates that gene expression profiles of cortical and hippocampal neuronal cultures captured the difference between genotypes
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Table 1 Enriched pathways in differentially expressed genes in brain and primary cultures of Fmr1KO mice
KEGG pathway (ENTREZ ID as input) p value No. of genes Fold enrichment
Hippocampal culture
mmu04910:Insulin signaling pathway 0.001 35 1.748
mmu03040:Spliceosome 0.001 32 1.801
mmu00900:Terpenoid backbone biosynthesis 0.002 8 3.796
mmu04720:Long-term potentiation 0.003 20 2.013
mmu04120:Ubiquitin mediated proteolysis 0.008 32 1.586
mmu04360:Axon guidance 0.009 31 1.584
mmu03010:Ribosome 0.011 22 1.740
mmu05211:Renal cell carcinoma 0.013 19 1.803
mmu04540:Gap junction 0.017 21 1.701
mmu04722:Neurotrophin signaling pathway 0.017 29 1.541
mmu00230:Purine metabolism 0.022 33 1.461
mmu00650:Butanoate metabolism 0.029 11 2.088
mmu04012:ErbB signaling pathway 0.031 21 1.603
mmu05215:Prostate cancer 0.038 21 1.567
mmu03018:RNA degradation 0.039 15 1.748
mmu03020:RNA polymerase 0.040 9 2.214
mmu00790:Folate biosynthesis 0.070 5 3.019
mmu04914:Progesterone-mediated oocyte maturation 0.078 19 1.485
mmu04150:mTOR signaling pathway 0.080 13 1.661
mmu00240:Pyrimidine metabolism 0.088 20 1.444
mmu05220:Chronic myeloid leukemia 0.088 17 1.506
Cortical culture
mmu04622:RIG-I-like receptor signaling pathway 0.001 23 2.027
mmu03040:Spliceosome 0.001 37 1.686
mmu04722:Neurotrophin signaling pathway 0.006 36 1.548
mmu04144:Endocytosis 0.012 48 1.395
mmu04660:T cell receptor signaling pathway 0.013 31 1.529
mmu04010:MAPK signaling pathway 0.016 63 1.308
mmu04120:Ubiquitin mediated proteolysis 0.018 36 1.444
mmu05220:Chronic myeloid leukemia 0.029 22 1.577
mmu04720:Long-term potentiation 0.052 19 1.548
mmu00534:Heparan sulfate biosynthesis 0.062 9 2.016
mmu03450:Non-homologous end-joining 0.076 6 2.481
mmu04062:Chemokine signaling pathway 0.080 41 1.267
mmu05210:Colorectal cancer 0.096 22 1.391
Hippocampus in situ
mmu04144:Endocytosis 0.013 14 2.133
mmu04060:Cytokine-cytokine receptor interaction 0.013 16 1.986
mmu05322:Systemic lupus erythematosus 0.014 8 3.088
mmu04514:Cell adhesion molecules (CAMs) 0.017 11 2.348
mmu05320:Autoimmune thyroid disease 0.028 6 3.451
mmu05330:Allograft rejection 0.051 5 3.523
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The genes down-regulated in murine Fmr1KO cultures
were enriched for MGI behavioral/neurological pheno-
type genes, human SFARI-related genes, and FMRP
targets. However, the overlap between these three lists
and differentially expressed genes in embryonic brain
tissue was not significant (Additional file 9: Table S9,
Additional file 10: Table S10 and Additional file 11:
Table S11). We also found a significant overlap between
SFARI and FMRP (p value = 4.41E−7), SFARI and MGI
behavioral (p value < 2.2E−16), FMRP and MGI behavioral
(p value = 1.03E−8) gene lists.
Differentially expressed genes in Fmr1KO in cultured
neurons are preferentially expressed in early human brain
development, whereas genes in embryonic hippocampal
and cortical tissues correspond more closely to later
developmental stages
To identify the predominant gene clusters in mice that
corresponded to developing human neocortex and hippo-
campus, we used PCA to compare 13,830 genes in sample
space in the two datasets, respectively. Our reference
model for development was the human neocortical and
hippocampal transcriptome at 15 stages, profiled using
Affymetrix Human Exon 1.0 ST Array as previously
described [25]. We integrated this reference data with our
mouse data, which comprised 21,141 unique genes. Of the
16,492 unique minimal human Entrez IDs present on
Affymetrix Exon ST 1.0 array, 14,653 genes correspond
with homologous mouse Entrez Gene ID and 13,830
unique genes are shared between the Human Exon 1.0ST
and Mouse 430 2.0 arrays (Additional file 12: Table S12).
Figure 2 shows the first two principal components for
each gene (each dot signifies a gene). In the hippocam-
pus, PC1 and PC2 captured 29 and 12 % of variation,
respectively, and in the neocortex, they captured 27.7
and 11.3 % of variation, respectively. Visually, there ap-
peared to be three large-scale patterns of co-expression
in each of the developmental time series represented on
PCA. Therefore, we used K-means clustering (k = 3) to
clarify these clusters. The first cluster primarily had
genes where the first PC was negative (PC1 < 0; H0 and
C0 in the hippocampus and cortex respectively; magenta
dots). Plotting these genes against developmental stage
showed that they were typically up-regulated between
the first and sixth stages of development and that their
expression decreased subsequently (median value for each
cluster based on RMA-normalized signal; right side of
Fig. 2). Stages 1 to 7 are defined as fetal stages in Kang et
al. [25]. Genes with a positive first PC1 (PC1 > 0) were
subdivided to two clusters, cluster 1 (green dots, H1/C1)
and cluster 2 (blue dots, H2/C2). Genes whose expression
was higher during developmental stages 7–11 are repre-
sented by H1 and C2 (infancy and childhood). H2 and C1
correspond primarily to genes up-regulated during young,
middle, and late adulthood. The border between H0/H1
and C0/C2 may be defined as birth, with its associated
broad changes in gene expression. Overall, we observed
that during human hippocampal development, 42 %
(5808), 31 % (4242), and 27 % (3780) of total genes resided
in H0, H1, and H2 clusters, respectively. During cortical
development, 40 % (5572), 30 % (4217), and 29 % (4041)
of total genes resided in the C0, C1, and C2 clusters,
respectively.
To investigate the expression profiles of murine homo-
logues in the human data, we highlighted differentially
expressed murine genes onto the human developmental
transcriptome map. Figure 3 shows differentially expressed
genes (blue: down-regulated, red: up-regulated, black: com-
bined) for hippocampal and cortical KO/WT cultures and
for embryonic hippocampus and cortex tissue.
The majority of genes that were up-regulated in mur-
ine Fmr1KO cortical and hippocampal cultures segre-
gated into cluster 0. This finding is indicated by the
increased density of red dots (genes) at the 9 o’clock
periphery of the upper panels in Fig. 3 and the highest
percentage in the corresponding cluster in Table 2. These
findings indicate that genes up-regulated in KO mice
tended to have increased expression in early development
(than later) of the corresponding brain area.
Next, we highlighted differentially expressed genes in
embryonic brain tissue in human development (Fig. 3c, d).
We observed that the majority of differentially regulated
Table 1 Enriched pathways in differentially expressed genes in brain and primary cultures of Fmr1KO mice (Continued)
mmu04672:Intestinal immune network for IgA production 0.082 5 2.998
mmu04610:Complement and coagulation cascades 0.099 6 2.415
Cortex in situ
mmu00590:Arachidonic acid metabolism 0.016 9 2.727
mmu04210:Apoptosis 0.029 9 2.439
mmu04640:Hematopoietic cell lineage 0.059 8 2.275
mmu04060:Cytokine-cytokine receptor interaction 0.064 16 1.623
mmu00601:Glycosphingolipid biosynthesis 0.083 4 3.838
Italics highlight pathways with p values <0.05
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genes in murine Fmr1KO primary hippocampus segre-
gated to Cluster H1, which represents a later stage in hu-
man development (Table 2). The majority of up-regulated
genes in murine Fmr1KO primary cortex segregated to
cluster 2 (C2). This finding indicates that the majority of
differentially expressed genes (mostly up-regulated genes
which partition to H1 and C2 in the hippocampus and
cortex) in primary brain tissue tended to be expressed at
higher levels in later development. Overall, differentially
expressed genes in murine culture were over-represented
for early expression in humans (cortical culture: 95 %
CI = 1.28–1.53, OR = 1.4; hippocampal culture: CI =
1.5–1.83, OR = 1.66), while the differentially expressed
genes in tissue were under-represented at early stages
(cortex: 95 % CI = 0.69–0.99, OR = 0.83; hippocampus:
95 % CI = 0.57–0.85, OR = 0.69) and over-represented
in later stages (Additional file 13: Table S13).
Next, we determined if enrichment of up-regulated
genes in KO mouse CNS in the early phases of develop-
ment was a consequence of common non-cell-type-
specific cell-cycle changes. We used the DAVID program
to perform a KEGG pathway-level analysis of the 732 C0-
and 821 H0-related up-regulated genes (red clusters in
Fig. 3a, b). This analysis showed that in addition to cell-
cycle-related processes, there was an over-representation
of processes such as the neurotrophin signaling pathway
and the T cell receptor signaling pathway in the C0-
related subset of genes. In addition, the insulin signaling
pathway, gap junction, endocytosis, ErbB signaling path-
ways and axon guidance were over-represented in the
H0-related subset of genes (Additional file 14: Table S14).
Discussion
The Fmr1KO mouse is a valuable model for studying
FXS and a subset of patients with autism. We selected
to work with FXS mouse model as it constitutes one of
the more established and studied models of the more
homogeneous monogenic forms of autism. Even so, we
accept that it might not be fully representative for
autism, which exhibits striking heterogeneity.
We investigated whether transcriptomic changes in
Fmr1KO embryonic brain tissues were paralleled by
Fig. 2 Integration of human GSE25219 and mouse data with cluster-representative profiles. The maps show gene-centric PCA (left panel) of 15
human developmental stages in hippocampus (top) and in cortex (bottom). Median profile for each cluster is represented on the right panel of
the figure
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Fig. 3 Differentially expressed murine genes highlighted on the human developmental transcriptome map. Differentially expressed genes in
Fmr1KO a hippocampal and b cortical culture are expressed early in human development and expressed late in c in situ hippocampus and d in
situ cortex (blue: down-regulated, red: up-regulated, black: combined)
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those obtained in cultured Fmr1KO neurons. Although
we found several commonalities, there were systematic
differences that were surprising to us and, to our know-
ledge, are previously unreported. For example, in the in
situ CNS of the Fmr1KO mouse, there was a significant
enrichment of genes involved in immunological signal-
ing; this pattern was not evident in cultured neurons.
Conversely, in cultured neurons, we found a perturb-
ation in several overlapping excitatory glutamatergic
signaling cascades. Most are downstream of mGluR and
neurotrophin signaling and may be coupled to FMRP-
regulated mRNA translation.
As indicated by PCA, the distance between KO and
WT clusters in cultures was higher than the distance
between KO and WT in intact embryonic brain tissue.
In addition, we observed a drastic difference in the num-
bers of differentially regulated genes in cultured cells
and intact brain. Both findings suggest that the murine
gene expression profile of cortical neuronal cultures and
hippocampal neuronal cultures captures the difference
between FXS and WT better than brain tissue. One
possible explanation for this finding is that the effects of
the Fmr1 mutation on gene expression are more directly
observable in cultured cells because of the more simplis-
tic nature of the model with fewer different cell types
and absence of a buffer to perturbation (culture). Pri-
mary brain is a complex tissue that can develop com-
pensatory mechanisms to disease and has many cell
types, with different gene expression patterns, therefore
diluting a particular phenotype. The phenotype is exag-
gerated in culture and subtle in the organism, with
factors not present in vitro playing a role in disease
pathogenesis and severity.
The findings in our cultured cells were congruent with
the well-established classical mGluR theory of FXS [1,
12, 13]. Specifically, we found significant perturbation in
LTP, neurotrophin signaling pathway, and mammalian
target of rapamycin (mTOR) and mitogen-activated pro-
tein kinase (MAPK) signaling cascades in Fmr1KO cul-
tures. Over-activation of these cascades could lead to
abnormal synaptic function owing to exaggerated protein
synthesis in FXS [2, 4]. Of the differentially expressed genes,
several are key activators in these aforementioned pathways
[2]. Several have also been implicated in autism-related
disorders [26], which have a high rate of comorbidity with
FXS. However, as a large percentage (15–60 %) of children
with FXS meet diagnostic criteria for autism, the findings
might be relevant to a specific subset of cases with autism.
Our findings support the hypothesis that the transcriptional
variation in this Fragile X model is focused within mGluR-
activated pathways related to synaptic plasticity.
Although the contrast between gene expression in
brain tissue and in cultured neurons in Fmr1KO is novel,
the finding of an immunological signal in the CNS is not.
A module enriched for immune genes and glial markers
has been observed in autism spectrum disorder (ASD)
human post-mortem brain tissue [27, 28], and immunity
response-related pathways were perturbed in Fmr1KO
and Tsc2+/− murine cerebellum [29]. Various studies
have implicated a dysregulated immune system response
in ASD [30–35], but the exact mechanisms by which
this dysfunction relates to autism-related disorders are
Table 2 Integration of human neocortex/hippocampus developmental genes and mouse differentially expressed genes in culture
and brain
Case/cluster H0 H1 H2 Case/cluster C0 C1 C2
All genes 5808 4242 3780 All genes 5572 4217 4041
% 42 31 27 % 40 30 29
Differentially expressed genes in cultured cells
Hippo culture KO/WT down 239 200 260 Cortex culture KO/WT down 428 461 408
% 34 29 37 % 33 36 31
Hippo culture KO/WT up 821 191 298 Cortex culture KO/WT up 732 268 168
% 63 15 23 % 63 23 14
Hippo culture KO/WT combined 1060 391 558 Cortex culture KO/WT combined 1160 729 576
% 53 19 28 % 47 30 23
Differentially expressed genes in primary brain tissue
Hippo brain KO/WT down 92 126 65 Cortex brain KO/WT down 102 52 57
% 32.5 44.5 23 % 48.3 24.6 27.1
Hippo brain KO/WT up 61 71 39 Cortex brain KO/WT up 96 81 162
% 35.7 41.5 22.8 % 28.3 24 47.7
Hippo brain KO/WT combined 153 197 104 Cortex brain KO/WT combined 198 133 219
% 33.7 43.4 22.9 % 36 24.2 39.8
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not well-established. Moreover, although the genes are
labeled as immunological in function, they also func-
tion as morphogens in the developing CNS [36].
Thus, their appearance in the intact CNS may mark a
change in development rather than the inflammatory
response they evince in the peripheral vasculature.
One possible explanation is that the end result of the
FMR1-related disorders is an immunological phenotype
that can be observed in the brain. However, culturing
cells frees them from environmental factors that influ-
ence this phenotype, allowing them to manifest the
synaptic-related dysfunctions of FXS. In addition, one of
the reasons why synaptic and/or neuronal effects were
more prominent in neuronal cultures may be because
the immunological changes are less visible due to the
lack of blood vessels or limited number and type of glia
in cultured neurons. Another explanation is the presence
of active glial cells in brain—especially microglia, which
are the brain’s professional phagocytes. Transformation
of microglia to reactive states in response to pathology
has been known for decades as microglial activation [37].
Neuroglial activation and neuroinflammation have been
observed in the brains of autism patients [28, 35, 38–40]
and reactive astrocytes in several brain regions of Fmr1KO
mice were previously revealed [41]. Moreover, the mor-
phological phenotype observed in Fmr1KO neurons—the
high density of dendritic spines [8–11]—might be linked
to pruning defects by microglial cells [42–45]. The im-
munological phenotype therefore adds to prior evidence
of a link between CNS pathology and glial activation
[46, 47] in Fmr1KO mice [41].
We used Human Brain Transcriptome data to construct
a map of genes that are active at different stages of human
brain development. We defined three clusters of genes cor-
responding to prenatal, early, and late developmental time
points in the cortex and hippocampus. We highlighted
human genes homologous to the differentially expressed
murine genes from culture and brain tissue, providing a
temporal analysis of the expression of these genes.
Up-regulated genes in KO cultures (as compared to
WT cultures) tended to be genes whose physiological
expression peaks early in healthy development. By
contrast, differentially expressed genes in brain tissues
were those whose expression peaks later in healthy
development. Up-regulated genes from intact KO murine
hippocampus and cortex were over-represented among
genes with later physiological expression in human
development. We hypothesize that the isolation and
culture of neurons caused cortex and hippocampus
cells to act “juvenile” or “de-differentiated” and therefore
to express a “younger” transcriptomic profile. We
have also found an enrichment of down-regulated
genes in Fmr1KO cultures in literature databases on
cognitive traits (MGI murine genes associated with
behavioral/neurological phenotype, human SFARI genes,
and FMRP binding targets). Together, we speculate that
KO cultures bear a greater resemblance to earlier stages of
development, and conversely, primary brain tissue bears a
stronger resemblance to later stages of development.
Conclusions
The findings from this study are summarized in Table 3
and highlighted in the list below:
1. There is an over-representation of immune-related
transcriptional activity in embryonic Fmr1KO cortex
and hippocampus in comparison to neuronal signaling
pathways in cortical and hippocampal primary cultures.
Importance: In addition to neuronal pathology,
research on disease treatments should also
consider the impact of immune dysregulation,
which is comparatively less studied.
Table 3 Summary of findings
Differentially expressed genes in Fmr1KO vs WT (disease genes)
Culture Brain
Hippocampus Cortex Hippocampus Cortex
Number of differentially expressed genes 2648 3372 726 866
Distance between KO and WT clusters on
PCA (PC1/PC2)
3.73/0.7 3.31/3.20 0.99/0.6 0.39/0.32
Pathway enrichment Neuronal processes Immune processes
Human development Early (H0 cluster) Early (C0 cluster) Later (H1 cluster) Later (C2 cluster)
Up-regulated Up-regulated Down- and up- regulated Up-regulated
SFARI human genes Significantly enriched in
down-regulated genes
Significantly enriched in
down-regulated genes
Not significant Not significant
MGI mouse genes associated with
behavioral/neurological phenotype
Significantly enriched in
down-regulated genes
Significantly enriched in
down-regulated genes
Not significant Not significant
FMRP targets Significantly enriched in
down-regulated genes
Significantly enriched in
down- and up- regulated genes
Not significant Not significant
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2. Up-regulated genes in murine KO cultures
corresponded to genes whose peak expression
occurs early in human development, while
differentially expressed genes measured in murine
KO embryonic brain tissue corresponded to genes
whose peak expression occurs later in human
development.
Importance: Cultured cells may recapitulate
an early phase of the disease, which is also less
obscured with “immunological” phenotype and in
vivo compensatory mechanisms.
3. Down-regulated differentially expressed genes in KO
cultures are enriched for (1) genes implicated in
autism (SFARI), (2) genes associated with
behavioral/neurological phenotypes of autism in
mice (MGI), and (3) FMRP binding targets.
Importance: These findings suggest that there are
potential shared disease-related mechanisms in
fragile X and other autism phenotypes in mice.
4. Together, these results suggest that the Fmr1KO
culture system:
– Better captures the difference between genotypes
in comparison to embryonic brain tissue.
– Bears greater resemblance to earlier stages of
human development
– Bears the significant resemblance to the genes
previously implicated with autism in human in
comparison to brain tissue
To conclude, cultured hippocampal and cortical cells
exhibited a more neurogenesis-related gene transcriptome,
while primary brain tissue exhibited a more immuno-
logical transcriptome. These results are consistent with
previous findings showing a role for the immunological
response in neurodevelopmental disorders. Fmr1KO dif-
ferentially expressed genes in culture coincided with genes
active in early human sdevelopment, while the brain-
related differentially expressed genes coincided with genes
more active later in human development.
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